RE:RE:RE:Not sitting wellAngusEast wrote: Thank you for posting this Nathaniel13....I've pulled the below quote out of the National Post article that you kindly shared. Intersting that MIR is mentioned in this article, with a link to their media releases. It would be nice to see Canadian and U.S. approvals over the coming weeks: A dozen companies are seeking Health Canada approval for serological tests, including Halifax-based MedMira Inc., whose rapid antibody test takes three minutes start to finish, using a drop of blood specimen.
Personally, I'm always a bit surprised to see anyone who doubts that MIR won't be a part of this huge population testing that governments and corporation are embarquing on. That is not to say that you are expressing any doubt - I'm talking about other posters.
Medmira's whole business is built on point-of-care rapid blood tests. Below is a cut-and-paste from their website. How could anybody read that and not feel that MIR is positioned exactly for this situation - it's their specialty. It would be like going to Midas Muffler and hearing that they can't fix your muffler or going to Moore's and hearing they don't have any suits. Almost inconceivable.
Medmira is an established Canadian company with a proven history in developing point-of-care rapid blood tests for antigen and antibody competing to develop point-of-care rapid blood tests for antigen and antibody during a global pandemic. Well, d'uh, how do we think this will go?
Our patented Rapid Vertical Flow Technology is the basis of MedMira’s robust product pipeline. It is a highly versatile product engine, enabling our team to quickly move new rapid testing applications through the discovery, design and development, and clinical phases to full commercialization. Our technology has been proven in highly complex regulatory markets around the world including the United States, Canada, Europe and China.
The technology facilitates the formation of highly specific antigen-antibody reactions allowing specific biomarkers in many sample types, including human whole blood, serum or plasma, to be captured and visualized on a unique membrane. The simple test procedure involves adding the specimen to the device and allowing it to flow through the membrane. If the specimen contains the target antibodies or antigens, they are captured on the test membrane and can be visually interpreted immediately after the addition of a detection reagent.
Our technology platform is unique in its ability to detect multiple biomarkers specific to several diseases using a single cartridge. Our Multiplo line of rapid tests for HIV, Hepatitis B and C, and syphilis uses the platform’s advanced capabilities to deliver up to four test results using one test cartridge and one drop of specimen.
Precision pipetting, sample manipulation, specialized equipment and training are not required to perform any of MedMira’s rapid tests, making it an invaluable diagnostic resource in a broad range of settings.